Shares of BioNTech SE were gaining around 3 percent in the morning trading in Germany as well as in the pre-market activity on Nasdaq after the German bio-tech company reported Monday significantly higher profit and revenues in its first quarter mainly with strong demand for Covid-19 vaccine. The company also reiterated its fiscal 2022 outlook for COVID-19 vaccine revenue.
from RTT - Earnings https://ift.tt/1wtflvN
via IFTTT
No comments:
Post a Comment